文献速递银屑病与炎症性皮肤病

法国成人银屑病患者自付费用:观察性横断面多中心研究

Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-12-08

该研究在法国纳入2562例临床确诊的银屑病患者,通过数字问卷评估自付费用。结果显示人均自付费用为531.00€,轻度、中度、重度分别为439.74€、791.06€、1077.64€,生殖器部位受累者中位费用显著更高(251.17€,P<0.001)。结论指出该费用超过2018年法国总体平均健康自付费用的两倍。

要点

  • 银屑病患者年均自付费用为531.00€,且随严重程度增加而升高。
  • 生殖器部位受累者的自付费用中位数显著高于面部或四肢受累者。
  • 超过90%的患者自付费用用于非处方产品和替代护理。

核心结论

  • 2019年法国银屑病患者自付费用平均为531.00€,超过2018年法国总体平均健康自付费用的两倍。

研究设计与样本

  • 观察性、横断面、非比较性、多中心研究,纳入3000例临床确诊的银屑病患者,最终2562例提供临床验证数据。

主要发现

  • 轻度、中度、重度银屑病患者自付费用均值分别为439.74€±939.85€、791.06€±1367.67€、1077.64€±1680.14€。
  • 生殖器部位受累者自付费用中位数为251.17€(95%CI [138.35;363.99]),显著高于面部(183.85€,95%CI [78.76;288.94])或四肢(199.96€,95%CI [93.77;306.15])(P<0.001)。
  • 超过90%的患者自付费用用于非处方产品(97.5%)和替代护理(92.0%),尤其是润肤剂和/或保湿产品。

临床怎么用

  • 临床医生应关注银屑病患者的自付费用负担,尤其是生殖器部位受累者。
  • 建议询问患者非处方产品和替代护理的支出情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2018 in France, overall mean health-related out-of-pocket (OOP) expenditures were 214.00€/year/patient. AIM: To evaluate OOP expenditures for psoriasis patients in France. METHODOLOGY: Observational, cross-sectional, non-comparative, multicentre study in 3000 patients with clinically confirmed psoriasis who responded to a specific digital questionnaire collecting demographic and socio-economic characteristics, assessing the 3 domains (severity, psychosocial impact and past history and interventions) of the patient's Simplified Psoriasis Index (sa-SPI) and expenditures to manage psoriasis, including OOP. Multivariate linear regression was conducted to search for factors associated with higher OOP. RESULTS: In total, 2681 patients completed the questionnaire and, of those, 2562 provided clinically validated data. Overall, 60% were women; the mean age was 49.4 ± 14.8 years. 30% of the patients declared that they suffered from psoriatic arthritis. The final mean sa-SPI core was 10.86 ± 9.70. Of these 2562 patients, 243 (9.5%) had severe, 442 (17.3%) moderate and 1877 (73.3%) mild psoriasis. In addition, 932 (36.4%) patients reported facial involvement, 724 (28.25%) genital impairment and 1124 (43.8%) lesions on the limbs. Mean OOP expenditures to manage psoriasis per patient were 531.00€, 439.74€ ± 939.85€ for patients with mild, 791.06€ ± 1367.67€ with moderate and 1077.64€ ± 1680.14€ for patients with severe psoriasis. For patients with psoriasis in the genital area, the median amount of expenditures (251.17€; CI95% [138.35;363.99]) was significantly higher than that for the face (183.85€; CI95% [78.76;288.94]) or limbs (199.96€; CI95% [93.77;306.15); (P < 0.001). More than 90% of the patients had OOP expenditures for over-the-counter products (97.5%) and alternative care (92.0%), especially for emollients and/or hydrating products. CONCLUSION: In France, in 2019, OOP expenditures to manage psoriasis were on average more than twice as high as the overall mean health-related OOP expenditures estimated by the French Health Agency in 2018. These results should lead health authorities to review certain standards of healthcare reimbursement.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Richard MA, Paul C, De Pouvourville G, et al. Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. J Eur Acad Dermatol Venereol. 2020. PMID: 33073410. doi:10.1111/jdv.17000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。